Management of splanchnic vein thrombosisKey points
Summary: The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | JHEP Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555922002397 |
| _version_ | 1797861075701465088 |
|---|---|
| author | Laure Elkrief Audrey Payancé Aurélie Plessier Louis d’Alteroche Maxime Ronot Valérie Paradis Dominique Valla Pierre-Emmanuel Rautou |
| author_facet | Laure Elkrief Audrey Payancé Aurélie Plessier Louis d’Alteroche Maxime Ronot Valérie Paradis Dominique Valla Pierre-Emmanuel Rautou |
| author_sort | Laure Elkrief |
| collection | DOAJ |
| description | Summary: The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, among which myeloproliferative neoplasms represent the most common; a rapid comprehensive work-up for risk factors of thrombosis is needed in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis and in those with porto-sinusoidal vascular liver disease. The presence and nature of underlying liver disease impacts the management of portal vein thrombosis. Indications for anticoagulation in patients with cirrhosis are growing, while transjugular intrahepatic portosystemic shunt is now a second-line option. Due to the rarity of these diseases, studies yielding high-grade evidence are scarce. However, collaborative studies have provided new insight into the management of these patients. This article focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, portal vein thrombosis without underlying liver disease, or cirrhosis with non-malignant portal vein thrombosis. |
| first_indexed | 2024-04-09T21:56:13Z |
| format | Article |
| id | doaj.art-43d2800d43b74f65b02355dc35a4443b |
| institution | Directory Open Access Journal |
| issn | 2589-5559 |
| language | English |
| last_indexed | 2024-04-09T21:56:13Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj.art-43d2800d43b74f65b02355dc35a4443b2023-03-24T04:23:14ZengElsevierJHEP Reports2589-55592023-04-0154100667Management of splanchnic vein thrombosisKey pointsLaure Elkrief0Audrey Payancé1Aurélie Plessier2Louis d’Alteroche3Maxime Ronot4Valérie Paradis5Dominique Valla6Pierre-Emmanuel Rautou7Service d’Hépato-Gastroentérologie CHU de Tours, FranceUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, FranceUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, FranceService d’Hépato-Gastroentérologie CHU de Tours, FranceUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; Service de radiologie, Hôpital Beaujon APHP.Nord, Clichy, FranceUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; Service d’anatomie et cytologie pathologique, Hôpital Beaujon APHP.Nord, Clichy, FranceUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, FranceUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France; Corresponding author. Address: Service d’Hépatologie, Hôpital Beaujon, 100 boulevard du Général Leclerc, 92110, Clichy, France; Tel.: +331 40 87 50 91, fax +331 40 87 44 35Summary: The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, among which myeloproliferative neoplasms represent the most common; a rapid comprehensive work-up for risk factors of thrombosis is needed in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis and in those with porto-sinusoidal vascular liver disease. The presence and nature of underlying liver disease impacts the management of portal vein thrombosis. Indications for anticoagulation in patients with cirrhosis are growing, while transjugular intrahepatic portosystemic shunt is now a second-line option. Due to the rarity of these diseases, studies yielding high-grade evidence are scarce. However, collaborative studies have provided new insight into the management of these patients. This article focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, portal vein thrombosis without underlying liver disease, or cirrhosis with non-malignant portal vein thrombosis.http://www.sciencedirect.com/science/article/pii/S2589555922002397CavernomaPortal biliopathyDirect oral anticoagulantsPortal vein recanalisationVascular liver diseases |
| spellingShingle | Laure Elkrief Audrey Payancé Aurélie Plessier Louis d’Alteroche Maxime Ronot Valérie Paradis Dominique Valla Pierre-Emmanuel Rautou Management of splanchnic vein thrombosisKey points JHEP Reports Cavernoma Portal biliopathy Direct oral anticoagulants Portal vein recanalisation Vascular liver diseases |
| title | Management of splanchnic vein thrombosisKey points |
| title_full | Management of splanchnic vein thrombosisKey points |
| title_fullStr | Management of splanchnic vein thrombosisKey points |
| title_full_unstemmed | Management of splanchnic vein thrombosisKey points |
| title_short | Management of splanchnic vein thrombosisKey points |
| title_sort | management of splanchnic vein thrombosiskey points |
| topic | Cavernoma Portal biliopathy Direct oral anticoagulants Portal vein recanalisation Vascular liver diseases |
| url | http://www.sciencedirect.com/science/article/pii/S2589555922002397 |
| work_keys_str_mv | AT laureelkrief managementofsplanchnicveinthrombosiskeypoints AT audreypayance managementofsplanchnicveinthrombosiskeypoints AT aurelieplessier managementofsplanchnicveinthrombosiskeypoints AT louisdalteroche managementofsplanchnicveinthrombosiskeypoints AT maximeronot managementofsplanchnicveinthrombosiskeypoints AT valerieparadis managementofsplanchnicveinthrombosiskeypoints AT dominiquevalla managementofsplanchnicveinthrombosiskeypoints AT pierreemmanuelrautou managementofsplanchnicveinthrombosiskeypoints |